Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis
暂无分享,去创建一个
A Orfao | E. Colado | A. Órfão | M. Santos-Silva | M. Jara-Acevedo | C Fernandez | M C Santos-Silva | A López | S Matarraz | M Jara-Acevedo | J Ciudad | M L Gutierrez | M L Sánchez | C Salvador-Osuna | M J Berruezo | J Á Díaz-Arias | A M Palomo-Hernández | E Colado | N González | D Gallardo | A Asensio | R García-Sánchez | R Saldaña | C Cerveró | A Carboné-Bañeres | O Gutierrez | M. Gutiérrez | D. Gallardo | J. Ciudad | S. Matarraz | C. Cerveró | A. Lopez | C. Fernández | A. Asensio | M. Berruezo | O. Gutiérrez | N. González | R. Saldaña | M. Sanchez | A. Carbone-Bañeres | R. García-Sánchez | C. Salvador-Osuna | J. Á. Díaz-Arias | A. M. Palomo-Hernández | Carlos Fernandez | A. Orfao | Maria-Luz Sanchez | David Gallardo
[1] A. Órfão,et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. , 2003, Cancer.
[2] C. Bloomfield,et al. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review , 2007, British journal of haematology.
[3] C. Bloomfield,et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? , 2007, Blood.
[4] K. Suzukawa,et al. Establishment of a novel human myeloid leukaemia cell line (HNT‐34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome , 1997, British journal of haematology.
[5] C. Pascutto,et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study , 2012, Haematologica.
[6] Shiang Huang,et al. Reactivating PP2A by FTY720 as a Novel therapy for AML with C‐KIT tyrosine kinase domain mutation , 2012, Journal of cellular biochemistry.
[7] T. Haferlach,et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML , 2010, Leukemia.
[8] B. Johansson,et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001 , 2002, Leukemia.
[9] A. Stukalov,et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia , 2012, American journal of hematology.
[10] F. Craig,et al. Flow cytometric immunophenotyping for hematologic neoplasms. , 2008, Blood.
[11] Ken Chen,et al. Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.
[12] A. Órfão,et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors , 2008, Leukemia.
[13] Martins Marta,et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia , 2003, Cancer.
[14] J. Rowley,et al. Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations. , 2002, American journal of clinical pathology.
[15] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[16] P. Marlton,et al. Molecular genetics of inversion 16 leukemia: implications for leukemogenesis. , 1996, Cancer treatment and research.
[17] H. Gundacker,et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations , 2006, British journal of haematology.
[18] D. Gilliland,et al. Genetics of myeloid leukemias. , 2003, Annual review of genomics and human genetics.
[19] D. Linch,et al. Quantification of X-chromosome inactivation patterns in haematological samples using the DNA PCR-based HUMARA assay. , 1996, Leukemia.
[20] A Orfao,et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes , 2012, Leukemia.
[21] R. Hast,et al. Differences in cell lineage involvement between MDS‐AML and de novo AML studied by fluorescence in situ hybridization in combination with morphology , 1997, European journal of haematology.
[22] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[23] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[24] Juergen Thiele,et al. The 2008 World Health Organization classification system for myeloproliferative neoplasms , 2009, Cancer.
[25] T. Kalina,et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols , 2012, Leukemia.
[26] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[27] R. Foà,et al. Immunophenotypic analysis in 119 patients with acute myeloid leukemia following a previous malignancy: a comparison with the immunophenotype of 231 de novo AML. , 2003, Haematologica.
[28] J. Stone,et al. Identification of masked and variant Ph (complex type) translocations in CML and classic Ph in AML and ALL by fluorescence in situ hybridization with the use of bcr/abl cosmid probes. , 1993, Cancer genetics and cytogenetics.
[29] M. Cazzola,et al. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group , 2012, Leukemia & lymphoma.
[30] T. Naoe,et al. Long‐term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single‐center experience , 2005, European journal of haematology.
[31] C. Tangen,et al. A Southwest Oncology Group study , 1993 .
[32] T. Kinoshita,et al. Clonality analysis by methylation-specific PCR for the human androgen-receptor gene (HUMARA-MSP) , 2000, Leukemia.
[33] O. Gadeberg,et al. Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML. , 2010, Cancer genetics and cytogenetics.
[34] B. Löwenberg. Diagnosis and prognosis in acute myeloid leukemia--the art of distinction. , 2008, The New England journal of medicine.
[35] A. Órfão,et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. , 2006, Blood.
[36] C. Bloomfield,et al. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. , 2006, Hematology. American Society of Hematology. Education Program.
[37] U. Lass,et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. , 2003, The American journal of pathology.
[38] D. Gilliland,et al. Core-binding factors in haematopoiesis and leukaemia , 2002, Nature Reviews Cancer.
[39] M. Fey,et al. Clonal X-inactivation analysis of human tumours using the human androgen receptor gene (HUMARA) polymorphism: a non-radioactive and semiquantitative strategy applicable to fresh and archival tissue. , 1997, Molecular and cellular probes.
[40] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[41] M. Tomonaga,et al. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group‐AML 92 study , 2003, British journal of haematology.
[42] M. Slovak,et al. Prognostic Impact of Acute Myeloid Leukemia Classification , 2003 .
[43] Guido Marcucci,et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. , 2006, Blood.
[44] C. Bloomfield,et al. Cytogenetics in Acute Leukemia , 2022 .
[45] A. Órfão,et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group , 2012, Leukemia.
[46] L. Mele,et al. The incidence of secondary leukemias. , 1999, Haematologica.
[47] M. Slovak,et al. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. , 2003, American journal of clinical pathology.
[48] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.
[49] A. Tefferi,et al. The diagnostic interface between histology and molecular tests in myeloproliferative disorders , 2007, Current opinion in hematology.
[50] W. Hiddemann,et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. , 1996, Leukemia.
[51] C. Bloomfield,et al. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances , 2007, Current opinion in hematology.
[52] J. Hernández-Rivas,et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients , 2010, Cytometry. Part B, Clinical cytometry.
[53] H. Preisler. Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML. , 2001, Cancer treatment and research.
[54] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[55] K. Bendix,et al. Reasons for treating secondary AML as de novo AML , 2010, European journal of haematology.
[56] E. Estey,et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. , 1995, Leukemia.
[57] Jennifer Clark,et al. Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. , 2002, Current opinion in oncology.
[58] R. Larson. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? , 2007, Best practice & research. Clinical haematology.